T he screening of newborn babies for congenital hypothyroidism has drastically changed the natural history of that condition, which represents the most common preventable cause of mental retardation. Most affected children gradually develop growth failure, irreversible mental retardation and a variety of neuropsychological de cits, comprising the syndrome of cretinism, 1,2 if treatment is delayed beyond about three months of life. [3] [4] [5] [6] [7] Studies have shown that 5-10% of newborn babies with congenital hypothyroidism are missed by primary screening programmes, regardless of whether the screening is for thyroxine (T4) or for thyroid-stimulating hormone (TSH). 8, 9 We describe here a female patient with congenital hypothyroidism that was missed by primary neonatal thyroid screening using TSH. The aim of this case report is to alert practitioners to the fact that undiagnosed cases of hypothyroidism will continue to present, despite screening programmes.
CASE HISTORY
The patient was born at full term, via normal vaginal delivery, to a primigravida Lebanese mother and nonconsanguineous Lebanese father. At birth her weight was 3780 g and her length 53.5 cm. Apgar scores were 9 and 10 at one and ve minutes, respectively. Her hospital stay was uneventful and she was discharged on her second day of life.
Her TSH level on neonatal screening was 2.3 mU/l (normal <20). The TSH screen was performed on the second day of life using dried blood spots by the Del a-Wallac neonatal screening method. The mother reported that she herself had had a goitre two years before her pregnancy. At that time she had tested positive for thyroid antibodies (anti-thyroglobulin and anti-peroxidase) but she tested negative for these antibodies just before her pregnancy and she did not receive any thyroid treatment during pregnancy. However, the same antibody levels were found to be mildly elevated two months after delivery: the anti-thyroglobulin was 224.6 kU/l (normal <50) and the anti-peroxidase was 20.5 kU/l (normal <10).
During the rst week of life the baby developed jaundice. She had been exclusively breast-fed, had normal bowel habits and was gaining weight adequately; she had no respiratory symptoms. Physical examination at the age of two weeks was unremarkable except for jaundice. The total serum bilirubin was 244.5 mmol/l (normal for age [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and the direct bilirubin 6.8 mmol/l (normal for age <3.4). Her leukocyte count was 14.1 ´10 9 cells/l (normal for age 5-21 10 9 ), haemoglobin was 180 g/l (normal for age 150-200), haematocrit was 0.55 (normal for age 0.46-0.62), platelets were 425 ´10 9 /l (normal for age 150-400 ´10 9 ), reticulocyte count was 0.001 (normal for age 0-0.1) and she did not have any reducing substances in the urine.
Breast-feeding was withheld for 24 hours. The child continued to have unconjugated hyperbilirubinaemia: total serum bilirubin was 256.5 mmol/l and the direct bilirubin was 5.1 mmol/l. At 20 days of life, her weight was 4100 g and she was still jaundiced. Thyroid function tests revealed a serum TSH level of over 100 mU/l (normal for age <10), free T4 0.52 pmol/l (normal for age 14.2-40.0) and free tri-iodothyronine (T3) 1.7 pmol/l (normal for age 3.4-7.7). She tested negative for both anti-thyroglobulin and antiperoxidase antibodies. The patient was immediately started on L-thyroxine, 50 mg daily, and breast-feeding was resumed.
Repeat thyroid function tests after two weeks of therapy showed a serum TSH of 0.9 mU/l, total T4 of 196.1 nmol/l (normal for age 92.9-201.2) and undetectable thyroglobulin. Repeat TSH determination on the initial screening sample using the same method was 2.4 mU/l.
On further follow-up, the jaundice of the patient disappeared, she continued to grow adequately and she reached her developmental milestones on time. Her thyroid function tests were continuously monitored every six months; there was full compliance with therapy. While on treatment, the girl's serum TSH rose, over four months, from 0.69 to 5.6 mU/l at two years of age (normal for age 0.3-5.0 mU/l), thus establishing the diagnosis of permanent rather than transient hypothyroidism with possible thyroid agenesis due to undetectable thyroglobulin. Consequently, the daily dose of L-thyroxine was increased from 50 mg to 75 mg. Ultrasound of the thyroid was not considered at the original diagnosis; however, at this stage it would not have affected the treatment of the baby. Additionally, discontinuation of treatment
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DISCUSSION
False-negative thyroid screenings do occur as a result of biological factors or screening errors. Laboratories in the US measure T4 on all specimens and TSH only if the T4 level is low. In most European states, and elsewhere in the world, TSH is the initial screening test. 8 Simultaneous measurement of both T4 and TSH has greater sensitivity for congenital hypothyroidism than either of the two sequential methods currently used 10 but it is generally not considered costeffective. 8, 10 Signi cant numbers of cases of hypothyroidism are missed because of human errors in sample collection, delivery to the laboratory, laboratory procedures or follow-up processes. In one study, the human errors were reported as one in 80,000 newborns. 11 Infants who are ill at birth, born at home or transferred between hospitals are at especially high risk of such errors. 12 False low TSH levels at initial screening are not necessarily due to methodological errors. In our case, a repeat determination of blood TSH was performed and was found to be normal. However, this does not preclude the possibility of an error in specimen collection or labelling. Regarding time of collection, the sample for initial screening was obtained before discharge on the second day of life, that is within the desirable period for collecting such samples (two to six days of age). 8 Given the low free T4 and free T3 levels at the time of the con rmation of hypothyroidism by serum assay, the blood spot (initial) TSH concentration was inexplicably low, which raises the possibility of a human error in the pre-analytical phase.
Hypothalamic-pituitary hypothyroidism, which has a prevalence of 1/50,000 to 1/100,000, 8, 12, 13 results in low or low-normal serum T4 concentration with normal or low or even slightly elevated TSH concentration, which would be missed by primary TSH screening. 9 Cases of primary hypothyroidism with dyshormonogenesis 8, 14 or thyroid dysgenesis (ectopia, aplasia and hypoplasia) 15, 16 may have low T4 and delayed TSH elevation (1/100,000), which may be missed on neonatal TSH screening. 8, 11 Transient TSH elevation is known to occur in association with iodine contamination, 17 maternal anti-thyroid antibodies or endemic iodine de ciency. 8 Our patient had increased TSH, low serum free T4 and free T3 and undetectable thyroglobulin; she also tested negative for anti-thyroid antibodies. The increase in serum TSH noted at two years of age while the patient was treated with L-thyroxine establishes the diagnosis of permanent congenital hypothyroidism rather than the transient type. 17 Regardless of the primary screening method used, the falsenegative rates are similar. 10 The sensitivity in the detection of these cases could be improved by repeat screening at two to six weeks of age. 18 Programmes in approximately 10 states in the US perform neonatal screening on specimens routinely collected at two time periods. 8 These programmes report that congenital hypothyroidism is detected in approximately 10% of the affected infants only as a result of collection of a second specimen. This represents an incidence of congenital hypothyroidism of 1/30,000 resulting from the second screening. 8 Routine collection of a second sample has drawbacks, such as increased cost of screening, the relatively low yield of cases, diversion and dilution of key personnel, and dif culties in implementing new programmes.
The average prevalence of congenital hypothyroidism in Lebanon is 1/1700, 19 which is more than twice the average prevalence (1/3000-4000) in other countries. 20 Increased prevalence of hypothyroidism is observed not only in Lebanon but also in other Arab countries, including Saudi Arabia. 21 A high incidence of consanguinity is a contributing factor, as is iodine de ciency, which may result in transient hypothyroidism. 22 In Lebanon there are around 70,000 births per year. 23 The estimated cost of a Lebanese programme for second screening is around US$250,000 per year and the average cost for managing a child with congenital hypothyroidism for his/her life span is US$300,000. 24 If the second screen detects one for every seven or eight cases of congenital hypothyroidism identi ed in the initial screen, then this second programme could result in a saving of US$6 for every US$1 spent on screening.
CONCLUSION
The screening of newborn babies for congenital hypothyroidism does not preclude the development of hypothyroidism later in infancy. Clinical vigilance must be maintained in order to detect the few cases that may be missed. An evaluation of the value and cost-effectiveness of a second programme of thyroid screening for early diagnostic con rmation between two and six weeks of age would be useful.
